ViaCell

What ViaCell does

ViaCell was founded in 1993 as a biotechnology company focused on women's health, with its cord blood banking operations eventually consolidated under the ViaCord brand. Today, ViaCord operates as a private cord blood and tissue banking service under parent company Revvity (NYSE: RVTY), a global diagnostics and life sciences company. The company's core technology centers on the cryogenic collection, processing, and long-term storage of hematopoietic stem cells (HSCs) from umbilical cord blood and mesenchymal stem cells (MSCs) from cord tissue, served by an FDA-registered, CLIA-certified, and AABB-accredited processing and storage laboratory outside Cincinnati, Ohio. ViaCord also operates an FDA-registered lab using the same freezer systems as the NIH and CDC, with samples housed in a FEMA-class vault under 24/7 monitoring.

ViaCord's product portfolio spans core banking services (Cord Blood Banking at $750 processing + $185/year storage; Cord Blood & Tissue Banking at $1,365 + $370/year) and a layered suite of genetic health add-ons, including Newborn Digestive Health ($250), Genetic Insights Panel (290+ genes), Whole Genome Sequencing ($2,500 newborn / $2,750 adult), and DNA Guardian ($175). Genetic sequencing is performed by sister company Revvity Omics, with results delivered through Genome Medical's telehealth genetic counseling network. The business runs primarily on a direct-to-consumer model — phone-based inside sales, self-serve e-commerce at viacord.com, and healthcare-provider-driven collection kit distribution — targeting expectant families in the U.S. and Puerto Rico. Revenue is generated through one-time processing fees combined with multi-year to lifetime (up to 78 years) recurring storage subscriptions, creating a long-duration annuity-like revenue stream on hundreds of thousands of stored samples.

ViaCell historically raised approximately $68 million in venture capital (a $48M round in 2000 led by Nomura International and a $20M round in 2004 led by Amgen Ventures), and acquired Kourion Therapeutics in 2003 to expand its therapeutic pipeline. The company was co-founded by Cynthia Fisher and Morey Kraus (CTO), and was originally public on NASDAQ under the ticker VIAC before being delisted and ultimately becoming part of Revvity.

Name

ViaCell

Legal name

ViaCord

Website

https://viacord.com

Company type

Private

Founded year

1993

Operating status

Operating

Headcount range

11–50 employees

Short description

ViaCell, founded in 1993, operates the ViaCord brand under Revvity (NYSE: RVTY), providing direct-to-consumer umbilical cord blood and tissue stem cell banking plus genetic health testing for expectant families across the U.S. and Puerto Rico.

Ownership category

akta.pro rank

Product category

Stem Cell Banking Services

NAICS

Blood and Organ Banks (621991), Medical Laboratories (621511)

SIC

Services-Medical Laboratories (8071), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Cell & Tissue Banking (biobanking, cord blood/tissue) (HLAAAGAE)

akta.pro secondary industries

Sample Logistics, Biorepository & IVD Kit Management (Trial Support) (HLAGAEAI), Genetic & Prenatal Testing Laboratories (HLAFAMAH), Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening) (HLAAALAJ)

Keywords

• Cord blood banking
• Cord tissue banking
• Newborn stem cell storage
• Genetic testing services
• DNA preservation

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Marketing or Sales, Technology or R&D, Supply Chain

Revenue model

1. Cord Blood Banking Services: One-time collection and processing fee plus annual stem cell storage subscription. Cord Blood Banking starts at $750 processing plus $185/year storage. Cord Blood & Tissue Banking at $1,365 processing plus $370/year storage. Multiple storage duration options including pre-pay plans for 5, 10, 20 years and lifetime storage (78 years) with increasing discounts.
2. Genetic Health Testing: Additional genetic tests using cord blood sample including Newborn Digestive Health ($250), Genetic Insights Panel (290+ genes, bundled with banking), and Whole Genome Sequencing ($2,500 for newborns, $2,750 for adults). Adult Whole Genome Sequencing offered via saliva kit at $2,750 one-time fee.
3. DNA Guardian Storage: One-time fee of $175 for preserving pristine newborn DNA sample for potential future genomic testing. No annual storage fee or fee for releasing sample.
4. ViaCord Complete Bundle: Comprehensive bundle covering Cord Blood & Tissue Banking, Newborn Digestive Health, and Newborn DNA Guardian at $1,790 plus storage, offering bundled pricing discount vs. individual services.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

ViaCell operates ViaCord, which cryogenically preserves Hematopoietic Stem Cells collected from newborn umbilical cord blood and Mesenchymal Stem Cells from cord tissue, with optional genetic health testing using a small sample of the banked cord blood. Processing and storage are performed at an FDA-registered, CLIA-certified, AABB-accredited lab outside Cincinnati, Ohio, operating 7 days a week, 365 days a year inside a FEMA-class vault. Customers pay a one-time processing fee plus annual storage and may layer on Whole Genome Sequencing, a 290+ gene Genetic Insights Panel, celiac/lactose predisposition testing, and a one-time DNA Guardian sample.

Product overview

ViaCord offers a portfolio of cord blood and tissue banking services centered on stem cell preservation at birth. The core offering is Cord Blood Banking ($750/year), which can be expanded to Cord Blood & Tissue Banking ($1,365/year) to capture both Hematopoietic Stem Cells and Mesenchymal Stem Cells. Additional genetic health insights are available as add-on modules: Newborn Digestive Health ($250) for celiac/lactose intolerance risk, Genetic Insights Panel for 290+ gene analysis, Whole Genome Sequencing ($2,500 newborn / $2,750 adult) for comprehensive genome analysis, and Newborn DNA Guardian ($175) for future testing. ViaCord Complete Services bundles cord blood/tissue banking with digestive health and DNA guardian. Services leverage cord blood and tissue samples collected at birth, with sequencing performed by sister company Revvity Omics and genetic counseling through Genome Medical.

Differentiator

Problem solved

Functional benefit

Products and services

• Cord Blood Banking Preserves Hematopoietic Stem Cells (HSCs) collected from a newborn's umbilical cord blood for potential use in stem cell transplants for nearly 80 conditions and in regenerative medicine clinical trials. Processing fee $750 plus $185/year storage, with multi-year prepay and installment options. Targets expectant families (B2C).
• Cord Blood & Tissue Banking Preserves both cord blood Hematopoietic Stem Cells and cord tissue Mesenchymal Stem Cells for expanded therapeutic potential across two distinct stem cell types, including conditions cord blood alone cannot address. Processing $1,365 plus $370/year storage. Targets expectant families (B2C).
• Newborn Digestive Health Genetic test analyzing cord blood for predisposition to celiac disease (HLA-DQ2/DQ8) and primary lactose intolerance (LCT gene). $250 add-on; requires Cord Blood Banking; not available in NY.
• Newborn DNA Guardian Preserves a sample of newborn's pristine DNA at ViaCord's lab for potential future genomic testing. One-time fee of $175 with no annual storage or release charges; requires Cord Blood Banking.
• Genetic Insights Panel Analyzes 290+ genes associated with actionable childhood-onset conditions, including 50+ ACMG medically actionable genes; results include a health action plan and genetic counselor support via Genome Medical. Bundled with Cord Blood Banking; not available in NY, NV, or OR.
• Whole Genome Sequencing (Newborn) Sequences all ~22,000 genes and analyzes 2,500 genes with known associations to childhood-onset conditions and drug sensitivities; sample can be re-analyzed in the future. $2,500 newborn one-time fee; requires Cord Blood Banking; not available in NV or OR.
• Whole Genome Sequencing (Adult) Sequences all ~22,000 genes and analyzes 6,000 genes with known associations to adult-onset conditions, carrier status, and drug sensitivities using saliva collection kit. $2,750 one-time fee; available without Cord Blood Banking; not available in NV or OR.
• ViaCord Complete Services Comprehensive bundle covering Cord Blood & Tissue Banking, Newborn Digestive Health, and Newborn DNA Guardian at $1,790 plus storage, with 6-month ($370/mo) and 12-month ($190/mo) installment options and $2,160 pay-in-full. Targets expectant families wanting all-inclusive coverage at a discount.

Quantifiable outcome

• Over 625 families have used their banked cord blood in stem cell transplants or regenerative medicine clinical trials
• +3 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• Revvity OmicscoreTechnology or IntegrationViaCord's sister company and the laboratory that runs Whole Genome Sequencing and Genetic Insights Panel testing services. Revvity Omics is described as a global leader in genomic testing.
• Genome MedicalcoreStrategic or Co-development PartnerGenome Medical provides genetic counselor services for ViaCord's Genetic Insights Panel and Whole Genome Sequencing tests. A Genome Medical physician orders tests and customers meet with a genetic counselor before and after testing. Genome Medical is the country's leading telehealth genetics care delivery company with clinical team across all 50 states.

Scale indicators5 records

Direct peers

• StemCyte: StemCyte operates both private and public cord blood banking programs with FDA-licensed processing and a focus on therapeutic applications. It competes with ViaCord for expectant-parent customers seeking family banking and transplant-grade storage.
• New England Cord Blood Bank: NECBB is a private and public hybrid cord blood bank providing family banking services with AABB accreditation and established relationships with hospitals. It competes with ViaCord on private banking for expectant families.
• Cord Blood Registry (CBR): CBR is one of the largest private family cord blood banks in the US, offering cord blood and cord tissue banking services to expectant parents. It is the most direct competitor to ViaCord on product, customer segment, and direct-to-consumer go-to-market.
• Cryo-Cell International: Cryo-Cell is a publicly traded private cord blood bank offering cord blood and menstrual stem cell banking. Like ViaCord, it sells directly to expectant families via subscription and one-time fees with annual storage, making it a closely comparable business.
• Americord Registry: Americord is a private cord blood and cord tissue bank with similar pricing tiers, AABB accreditation, and a direct-to-consumer sales model targeting expectant families, overlapping closely with ViaCord's core offering.

Emerging players

• Natera: Natera is a reproductive and oncology genetic testing company offering carrier screening, NIPT, and other DNA-based tests. It is comparable to ViaCord's genetic testing add-on line (Whole Genome Sequencing, Genetic Insights Panel) for the same expectant-parent customer base.

Broad incumbents

• Myriad Genetics: Myriad is an established clinical genetics and molecular diagnostics company offering hereditary cancer, pharmacogenomic, and other genetic tests. It is comparable as a broader-scale incumbent in the same genetic-testing space that ViaCord is expanding into with its WGS and Genetic Insights Panel offerings.
• Revvity (parent company): Revvity is ViaCord's publicly traded parent and a global diagnostics and life sciences platform that also provides sequencing through Revvity Omics. It is comparable as the broader corporate context for valuing ViaCord and as a potential acquirer or strategic partner.
• CooperSurgical: CooperSurgical owns CBR (Cord Blood Registry) and operates broadly in women's health, fertility, and reproductive services. It is comparable as a broader incumbent competitor that owns ViaCord's most direct peer and operates in adjacent OB/GYN and fertility channels.

Others

• Genome Medical: Genome Medical is the telehealth genetic counseling partner used by ViaCord for its WGS and Genetic Insights Panel offerings. It is comparable as an ecosystem enabler whose services underpin ViaCord's higher-end genetic test experience.

Market position

Strengths4 records

Weaknesses5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/viacord
• YouTubeyoutube.com/viacordvideos
• Facebookfacebook.com/viacord
• Instagraminstagram.com/viacord
• LinkedInlinkedin.com/company/viacord

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds2 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ViaCell